A New Targeted Therapy Strategy for Lymphoma

Robert Peter Gale

doi:10.1002/mco2.70529

MedComm ›› 2025, Vol. 6 ›› Issue (12) :e70529 DOI: 10.1002/mco2.70529

HIGHLIGHT

A New Targeted Therapy Strategy for Lymphoma

Robert Peter Gale

Author information +

History +

PDF

Cite this article

Download citation ▾

Robert Peter Gale. A New Targeted Therapy Strategy for Lymphoma. MedComm, 2025, 6(12): e70529 DOI:10.1002/mco2.70529

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Y. G. Shen, Q. Shi, W. Tang, et al., “Genetic Subtype-Guided Immunochemotherapy in Relapsed and Refractory Diffuse Large B Cell Lymphoma: A Phase 2 Investigator-Initiated Nonrandomized Clinical Trial (Guidance-06),” Signal Transduction and Targeted Therapy 10, no. 1 (2025): 232.

[2]	M. C. Zhang, S. Tian, D. Fu, et al., “Genetic Subtype-Guided Immunochemotherapy in Diffuse Large B Cell Lymphoma: The Randomized Guidance-01 Trial,” Cancer Cell 41, no. 10 (2023): 1705–1716.e5.

[3]	R. Shen, D. Fu, L. Dong, et al., “Simplified Algorithm for Genetic Subtyping in Diffuse Large B-Cell Lymphoma,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 145.

[4]	M. Mingalimov, E. Baryakh, D. Ivanova, et al., “Personalized Genetically Adapted Therapy for Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Single-Center Prospective Study,” poster presented at European Hematology Association 2025 Congress (virtual), June 12, 2025.

[5]	J. H. Liang, H. R. Shen, H. Yin, et al., “Novel Targeted Agents in Combination With R-Mine (Rmine+X) Based on Different Molecular Subtypes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Multicenter Study,” Blood 144, no. S1 (2024): 1725–1726.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.